Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 9/2012

01-09-2012 | Research Article

Chemotherapy at the end of life: up until when?

Author: Jaime Sanz Ortiz

Published in: Clinical and Translational Oncology | Issue 9/2012

Login to get access

Abstract

Aim

The aim of this study is to analyze the use of CT in terminal stage cancer and the percentage of patients who received UCPD in 2009 and 2010 on the Medical Oncology and Palliative Home Care integrated service (UCPD) ward of the Marqués de Valdecilla University Hospital.

Method

Retrospective analysis of death rate registered on the Medical Oncology ward for 2009 and 2010 and the recorded date of the last CT given. The data are analyzed using the SPSS version 15.0 statistic package. Data were obtained from the Database Minimum Set for oncology admissions.

Results

The death rate on the Medical Oncology ward is 22–24 %. Total number of cases studied is 303. 47 % of patients are aged 60 or younger. 81.8 % (248) received active cancer treatment; of these, 138 (55.6 %) in the last month, and 84 (33.8 %) in the last 2 weeks. Only 66 patients out of those who died on the ward (21 %) were previously sent to the UCPD.

Conclusions

Even when it is known that the majority of cancer patients become resistant to CT at the end of their lives, it is often given to patients of all ages. The request for palliative care is rare and often late.
Literature
1.
Lorenz KA, Lynn J, Dy SM, Shugarman LR, Wilkinson A, Mularski RA et al (2008) Evidence for improving palliative care at the end of the life: a systematic review. Ann Intern Med 148:147–159PubMed
2.
Ferlay J, Bray F, Pisani P, Parkin DM (2001) GLOBOCAN 20.00: cancer incidence, mortality and prevalence word wide. Version 1.0. IARC CancerBase N. 5.Lyon IARC Press
3.
Natale RB, Zaretsky SusanL (2002) ZD1839 (Iressa™): what’s in it for the patient? Oncologist 7(suppl 4):25–30PubMedCrossRef
4.
5.
Sanz-Ortiz J (2002) Oncología Médica y Cuidados Paliativos. Estudio de campo. VIII Congreso Nacional de Oncología Médica, 6–9 Octubre Hotel Meliá Valencia 2002. Libro de Ponencias: p 121; Sociedad Española de Oncología Médica (SEOM)
6.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistic 2006. CA Cancer J Clin 56:106–130PubMedCrossRef
7.
8.
Sanz Ortiz J (2003) Nuevas dianas moleculares en la terapia del cáncer ¿Tienen función paliativa? Med Pal (Madrid) 10(4):220–225
9.
Murillo RJ, Koeller J (2006) Chemotherapy given near the end or life by community oncologist for advanced non-small cell lung cancer. Oncologist 11:1095–1099PubMedCrossRef
10.
Raby B, Pater J, Mackillop W (1995) Does knowledge guide practice? Another look at the management of non-small cell lung cancer. J Clin Oncol 13:1904–1911PubMed
11.
Silvestri G, Pritchard R, Welch HG (1998) Preferences for chemotherapy in patients with non-small cell lung cancer: descriptive study based scripted interviews. BMJ 317:771–775PubMedCrossRef
12.
13.
Earle CC, Landrum MB, Souza JM, Neville V, Weeks JC, Ayanian JZ et al (2008) Aggressiveness of cancer near the end of life: is it a quality-of-care issue? J Clin Oncol 26:3860–3866PubMedCrossRef
14.
Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Vicki AJ, Constance MD, Craig DB, Juliet J, William FP, Andrew B, Thomas JL (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363(8):733–742PubMedCrossRef
15.
16.
17.
Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Arlene SA (2003) Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med 138:639–643PubMed
18.
Yun YH, Miyoung K, Sang Min P, Samyong K, Jong Soo C, Ho-Yeong L, Chang Geol L, Youn Seon C, Youn Seon H, Si-Young K, Dae Seog H (2007) Chemotherapy use and associated factors among cancer patients near the end of life. Oncology 72:164–171PubMedCrossRef
19.
Hashimoto K, Yonemori K, Katsumata N, Hotchi M, Kouno T, Shimizu C, Tamura K, Ando M, Takeuchi M, Fujiwara Y (2009) Factors that affect the duration of the interval between the completion of palliative chemotherapy and death. Oncologist 14:752–759. http://​www.​TheOncologist.​com
20.
Sahm S, Will R, Hommel G (2005) What are cancer patients’ preferences about treatment at the end of life, and who should start talking about it? A comparison with healthy people and medical staff. Support Care Cancer 13:206–214PubMedCrossRef
21.
Sánchez- Muñoz A, Pérez-Ruiz E, Sáez MI, Trigo JM, Galindo MM, Manzaneque L, Jiménez B, Muros B, Alba E (2011) Limited impact of palliative chemotherapy on survival in advanced solid tumours in patients with poor performance status. Clin Transl Oncol 13(6):426–429PubMedCrossRef
22.
Romaní Costa V, López E, Rodríguez Carballeira M, Almagro Mena P (2010) Morir en un hospital de agudos. Análisis de la situación de últimos días. Med Pal (Madrid) 17(4):222–225
23.
NCCN Clinical Practice Guidelines in Oncology (2008) Palliative care V.1.2008. Standards of Palliative Care (Pal-1)
24.
Huskamp HA, Keating NL, Malin JL, Zaslavsky AM, Weeks JC, Earle CC, Teno JM, Virnig BA, Kahn KL, He Y, Ayanian JZ (2009) Discussion with physicians about hospice among patients with metastatic lung cancer. Arch Intern Med 169:954–962PubMedCrossRef
25.
Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC (2004) Trends in aggressiveness of cancer care the end of life. J Clin Oncol 22:315–321PubMedCrossRef
26.
Malin JL (2004) Bridging the divide: integrating cancer-directed therapy and palliative care. J Clin Oncol 22:3438–3440PubMedCrossRef
27.
28.
Cherny NI, Portenoy NK (1994) Sedation in the management of refractory symptoms: guidelines for evaluation and treatment. J Palliat Care 10(2):31–38PubMed
29.
Porta-Sales J, Núñez Olarte JM, Altisent Trota R, Bisbert Aguilar A, Loncan Vidal P, Muñoz Sánchez D et al (2002) Aspectos éticos de la sedación en cuidados paliativos. Med Pal (Madrid) 9(1):41–46
30.
Doyle D (1992) Have we looked beyond the physical and psychosocial? J Pain Symptom Manag 7(5):302–311CrossRef
31.
Sanz Ortiz J, Martín Carnicero A (2009) Desasosiego o “disconfortabilidad”: ¿un síntoma refractario en la fase final de la vida? Med Clin (Barc) 132(17):669–670CrossRef
32.
Porta Sales J, Ylla-Catalá Boré A, Estibalez Gil I, Griman Malet A, Lafuerza Torres M, Nabal Vicuña C et al (1994) Estudio multicéntrico catalana-balear sobre la sedación Terminal en Cuidados Paliativos. Med Pal (Madrid) 6(4):153–158
33.
Sulmasy DP, Pellegrino ED (1999) The rule of double effect: clearing up the double talk. Arch Intern Med 159:545–550PubMedCrossRef
34.
Quill TE, Dresser R, Brock DW (1997) The rule of double effect a critique of its role in end-of-life decision making. N Engl J Med 337:1768–1771PubMedCrossRef
35.
Sanz Ortiz J (2008) La sedación paliativa como lex artis en el cuidado del final de la vida. PSICOONCOLOGÍA 5(2–3):265–277
36.
Alvarado-Cabrero I (2007) La autopsia: ¿ha muerto? Rev Med Mex Seguro Soc 45(1):1–2
37.
Burton JL, Underwood J (2007) Clinical, educational, and epidemiological value of autopsy. Lancet 369(9571):1471–1480PubMedCrossRef
38.
Petri CAN (1993) Decrease in the frequency of autopsies in Denmark after the introduction of a new Autopsy Act. Int J Qual Health Care 5:315–318CrossRef
39.
Horowitz RE, Naritoku WY (2007) The autopsy as a performance measure and teaching tool. Human Pathol 38:688–695CrossRef
40.
Skrabanek P (ed) (1999) La ideología de la salud. En: La muerte de la medicina con rostro humano. Diaz Santos S. A. Madrid, pp 1–35
41.
Bakitas M, Lyons KD, Hegel MT, Balan S, Brokaw FC, Seville J, Hull JG, Li Z, Tosteson TD, Byock IR, Ahles TA (2009) Effects of palliative care intervention on clinical outcomes in patients with advanced cancer. The project ENEABLE II Randomized Controlled Trial. JAMA 302(7):741–749PubMedCrossRef
42.
Thomas JS, Bruce EH (2011) Bending the cost in cancer care. N Engl J Med 364(21):2060–2065CrossRef
43.
Gómez- Batiste X, Tuca A, Porta-Sales J, Amor M, Espinosa J, Borrás JM, De la Mata I, Castellsagué J (2006) Resource consumption and cost of palliative care servicies in Spain: a multicenter prospective study. J Pain Symptom Manage 31(6):522–532PubMedCrossRef
44.
Hui D, Elsayem A, De la Cruz M et al (2010) Availability an integration of palliative care at USS cancer centers. JAMA 303:1054–1061PubMedCrossRef
45.
Dalal Sh, Palla Sh, Hui D, Li N, Chacko R, Li Zh, Fadul N, Scott Ch, Thorton V, Colman B, Amin Y, Bruera E et al (2011) Association between a name change from palliative to supportive care and the timing of patient referrals at a Comprehensive Cancer Center. Oncologist 16:105–111PubMedCrossRef
46.
Sanz Ortiz J (2011) Quimioterapia en la fase final de la vida: ¿es compasiva? Med Clin (Barc) 136(8):343–344CrossRef
47.
(1998) Cancer care during the last phase of life. ASCO SPECIAL ARTICLE. J Clin Oncol 16:1986–1996
Metadata
Title
Chemotherapy at the end of life: up until when?
Author
Jaime Sanz Ortiz
Publication date
01-09-2012
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 9/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0847-6

Other articles of this Issue 9/2012

Clinical and Translational Oncology 9/2012 Go to the issue

Educational Series – Red Series*

Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment?

Research Article

Searching for Hif1-α interacting proteins in renal cell carcinoma

Research Article

Clinical safety of induced CTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients

Research Article

Trends in the lung cancer incidence and mortality in the Slovak and Czech Republics in the contexts of an international comparison

Correspondence

In answer to: “Comments to SEOM clinical guidelines for the treatment of thyroid cancer” by Garcilaso Riesco-Eizaguirre et al

Editorial

Promises and pitfalls of new technology in radiotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits